Levofloxacin Hikma (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition prevents bacterial cells from dividing, leading to rapid bactericidal activity against a broad range of Gram‑negative and Gram‑positive organisms.

The dosage of Levofloxacin Hikma is determined by the prescribing physician according to the type and severity of infection, patient weight, renal function, and other clinical factors. The prescriber sets the exact dose and duration.

Levofloxacin is classified as pregnancy category unknown. It should be used during pregnancy or lactation only when the potential benefit justifies the potential risk to the fetus or infant. The prescribing clinician must evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levofloxacin is a third‑generation fluoroquinolone with enhanced activity against Gram‑positive organisms compared with older agents like ciprofloxacin. It offers once‑daily dosing for many infections and a favorable safety profile, though all fluoroquinolones share class‑related warnings such as tendon toxicity and QT prolongation.

Levofloxacin Hikma should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze the product, and avoid exposing it to excessive heat or moisture to maintain stability.

Levofloxacin Hikma is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified health professional. The infusion rate and duration are set by the prescriber based on the clinical scenario.

Serious risks include tendon rupture, especially in older adults or those on corticosteroids; QT interval prolongation leading to arrhythmias; severe allergic reactions such as anaphylaxis; and Clostridioides difficile‑associated colitis. Patients should be monitored closely for these events.

Levofloxacin should be avoided in patients with a known hypersensitivity to fluoroquinolones, a history of tendon disorders related to quinolone use, or those with significant QT prolongation. Caution is also advised for patients with severe renal impairment unless dose adjustments are made.